Search and Browse
Download
Enter Data
| Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411333 (US10385031, Compound 039) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411335 (US10385031, Compound 041) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411337 (US10385031, Compound 043) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411344 (US10385031, Compound 050) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411347 (US10385031, Compound 053) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411360 (US10385031, Compound 066) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411373 (US10385031, Compound 079) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411328 (US10385031, Compound 034) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411331 (US10385031, Compound 037) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411345 (US10385031, Compound 051) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411346 (US10385031, Compound 052) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411362 (US10385031, Compound 068) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411377 (US10385031, Compound 083) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411380 (US10385031, Compound 086) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411381 (US10385031, Compound 087) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411384 (US10385031, Compound 090) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411329 (US10385031, Compound 035) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411332 (US10385031, Compound 038) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411334 (US10385031, Compound 040) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411341 (US10385031, Compound 047 | US10385031, Compound 04...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411361 (US10385031, Compound 067) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411370 (US10385031, Compound 076) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411334 (US10385031, Compound 040) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411342 (US10385031, Compound 048) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411333 (US10385031, Compound 039) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411359 (US10385031, Compound 065) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411369 (US10385031, Compound 075) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411376 (US10385031, Compound 082) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411380 (US10385031, Compound 086) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411345 (US10385031, Compound 051) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411358 (US10385031, Compound 064) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411365 (US10385031, Compound 071) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411382 (US10385031, Compound 088) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411330 (US10385031, Compound 036) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411336 (US10385031, Compound 042) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411340 (US10385031, Compound 046) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411348 (US10385031, Compound 054) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411364 (US10385031, Compound 070) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411374 (US10385031, Compound 080) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411341 (US10385031, Compound 047 | US10385031, Compound 04...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411347 (US10385031, Compound 053) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411368 (US10385031, Compound 074) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411374 (US10385031, Compound 080) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411379 (US10385031, Compound 085) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <10 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411355 (US10385031, Compound 061) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411356 (US10385031, Compound 062) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411357 (US10385031, Compound 063) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411363 (US10385031, Compound 069) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411378 (US10385031, Compound 084) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411342 (US10385031, Compound 048) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411349 (US10385031, Compound 055) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411355 (US10385031, Compound 061) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411341 (US10385031, Compound 047 | US10385031, Compound 04...) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411353 (US10385031, Compound 059) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411354 (US10385031, Compound 060) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411356 (US10385031, Compound 062) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411357 (US10385031, Compound 063) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411372 (US10385031, Compound 078) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411354 (US10385031, Compound 060) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411357 (US10385031, Compound 063) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411354 (US10385031, Compound 060) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411356 (US10385031, Compound 062) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411350 (US10385031, Compound 056) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411372 (US10385031, Compound 078) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411378 (US10385031, Compound 084) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411337 (US10385031, Compound 043) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411351 (US10385031, Compound 057) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411367 (US10385031, Compound 073) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411378 (US10385031, Compound 084) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411338 (US10385031, Compound 044) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411349 (US10385031, Compound 055) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411351 (US10385031, Compound 057) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411375 (US10385031, Compound 081) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411355 (US10385031, Compound 061) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | >500 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411370 (US10385031, Compound 076) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411382 (US10385031, Compound 088) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411328 (US10385031, Compound 034) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411332 (US10385031, Compound 038) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411333 (US10385031, Compound 039) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411334 (US10385031, Compound 040) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411336 (US10385031, Compound 042) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411342 (US10385031, Compound 048) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411353 (US10385031, Compound 059) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411360 (US10385031, Compound 066) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411362 (US10385031, Compound 068) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411372 (US10385031, Compound 078) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411379 (US10385031, Compound 085) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411383 (US10385031, Compound 089) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411328 (US10385031, Compound 034) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411329 (US10385031, Compound 035) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411330 (US10385031, Compound 036) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411339 (US10385031, Compound 045) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411341 (US10385031, Compound 047 | US10385031, Compound 04...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411341 (US10385031, Compound 047 | US10385031, Compound 04...) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411344 (US10385031, Compound 050) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411345 (US10385031, Compound 051) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411348 (US10385031, Compound 054) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411350 (US10385031, Compound 056) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411352 (US10385031, Compound 058) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411359 (US10385031, Compound 065) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411361 (US10385031, Compound 067) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411374 (US10385031, Compound 080) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411376 (US10385031, Compound 082) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411331 (US10385031, Compound 037) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411335 (US10385031, Compound 041) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411339 (US10385031, Compound 045) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411350 (US10385031, Compound 056) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411361 (US10385031, Compound 067) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411364 (US10385031, Compound 070) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411367 (US10385031, Compound 073) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411369 (US10385031, Compound 075) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411370 (US10385031, Compound 076) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411375 (US10385031, Compound 081) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411381 (US10385031, Compound 087) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411382 (US10385031, Compound 088) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411330 (US10385031, Compound 036) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411336 (US10385031, Compound 042) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411346 (US10385031, Compound 052) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411346 (US10385031, Compound 052) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411347 (US10385031, Compound 053) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411348 (US10385031, Compound 054) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411352 (US10385031, Compound 058) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411352 (US10385031, Compound 058) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411358 (US10385031, Compound 064) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411360 (US10385031, Compound 066) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411362 (US10385031, Compound 068) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411368 (US10385031, Compound 074) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411371 (US10385031, Compound 077) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411377 (US10385031, Compound 083) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411384 (US10385031, Compound 090) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411384 (US10385031, Compound 090) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411340 (US10385031, Compound 046) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411341 (US10385031, Compound 047 | US10385031, Compound 04...) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411358 (US10385031, Compound 064) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411365 (US10385031, Compound 071) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411366 (US10385031, Compound 072) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411367 (US10385031, Compound 073) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411369 (US10385031, Compound 075) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411371 (US10385031, Compound 077) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411373 (US10385031, Compound 079) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411379 (US10385031, Compound 085) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411380 (US10385031, Compound 086) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411383 (US10385031, Compound 089) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411332 (US10385031, Compound 038) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411338 (US10385031, Compound 044) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411338 (US10385031, Compound 044) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411340 (US10385031, Compound 046) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411353 (US10385031, Compound 059) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411359 (US10385031, Compound 065) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411364 (US10385031, Compound 070) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411371 (US10385031, Compound 077) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411373 (US10385031, Compound 079) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411375 (US10385031, Compound 081) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411377 (US10385031, Compound 083) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411329 (US10385031, Compound 035) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411331 (US10385031, Compound 037) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411335 (US10385031, Compound 041) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411337 (US10385031, Compound 043) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411339 (US10385031, Compound 045) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411344 (US10385031, Compound 050) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411349 (US10385031, Compound 055) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411351 (US10385031, Compound 057) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411363 (US10385031, Compound 069) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411365 (US10385031, Compound 071) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411366 (US10385031, Compound 072) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 3 (Homo sapiens (Human)) | BDBM411368 (US10385031, Compound 074) | PDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411376 (US10385031, Compound 082) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411381 (US10385031, Compound 087) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 1 (Homo sapiens (Human)) | BDBM411383 (US10385031, Compound 089) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411363 (US10385031, Compound 069) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Histone deacetylase 2 (Homo sapiens (Human)) | BDBM411366 (US10385031, Compound 072) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | <1.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
REGENACY PHARMACEUTICALS, LLC US Patent | Assay Description Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were... | US Patent US10385031 (2019) BindingDB Entry DOI: 10.7270/Q28P62WR | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
